MC for other health conditions

Loading...

來自 Technion - Israel Institute of Technology 的課程

Medical Cannabis for Pain Control

6 個評分

Technion - Israel Institute of Technology

Medical Cannabis for Pain Control

6 個評分

Cannabis is a group of flowering plants that has been long used for industrial, recreational and medical purposes. When relating to its medical use, the terms "Medical Cannabis" or "Medical marijuana" has become prevalent. In this course we will use the term "Medical Cannabis". Nowadays, Medical Cannabis involves multiple medical disciplines such as neuroscience, pain, pharmacology, oncology, psychiatry and more. Moreover, it has cultural, agricultural and social, legal and political implications. This course will give you a solid ground to understand the whole picture. By completing this course, you will gain a broad understanding and knowledge base related to medical use of cannabis for pain control. You will be exposed to a wide range of topics such as historical use of cannabis in ancient times, botanic aspects of the plants, and potential benefits and risks associated with its medical use to both individuals and society.

從本節課中

Effectiveness of cannabis on other conditions

Psychiatric conditions5:39

Neurological conditions11:07

MC for other health conditions4:07

與講師見面

Elon Eisenberg
Professor of Neurology and Pain Medicine
Institute of Pain Medicine, Rambam Health Care Campus

Glaucoma refers to a group of five diseases

which result in damage to the optic nerve and vision loss.

A major risk factor of glaucoma is increased pressure in the eye.

Ophthalmologist treat glaucoma by lowering the intraocular pressure with medications,

or surgical interventions if necessary.

There has been an ongoing interest in the use of

medical cannabis for glaucoma since the 70s,

when reports that smoking marijuana lowers intraocular pressure began to emerge.

There is clear evidence,

as expressed by numerous studies,

that smoked and orally administered cannabis can lower

intraocular pressure by some 25 percent in approximately two-thirds of patients.

There are a couple of serious drawbacks, however.

First, reduced intraocular pressure might be associated to lower blood pressure,

a known effect of cannabis consumption,

which may reduce blood flow to the optic nerve and damage it.

Second, the effect is only temporary,

and typically lasts for no more than 3-4 hours,

no matter the dose.

In other words, in order to achieve constant lowering of intraocular pressure,

cannabis has to be consumed every 3-4 hours around the clock.

These drawbacks raise obvious concerns which led

the American Academy of Ophthalmology to state in

2014 that it does not recommend

marijuana or other cannabis products for the treatment of glaucoma.

Epilepsy at childhood usually begins in the first few years of

life and is frequently characterized by seizures that can be resistant to treatment.

If severe, these can delay child development,

and significantly impair quality of life of both the child and the family.

Public and professional interest in the use of medical cannabis for

the treatment of childhood epilepsy has grown in the past few years.

A recent survey from Stanford University

reports a dramatic decrease in the number of seizures from

cannabidiol-enriched cannabis in 16 of 19 children with resistant epilepsy;

80-100 percent reduction was reported by half of the parents.

Children showed increased alertness,

better mood, and improved sleep with minimal side effects.

Due to the absence of psychoactive effects in cannabidiol,

the use of cannabidiol-enriched cannabis has major advantages,

and notably in children.

A new CBD product known as a Epidiolex,

has been developed for the treatment of severe intractable epilepsy.

And initial reports of its use in

137 children shows an overall 54 percent reduction in seizures' frequency.

At three months, nine percent of the children were seizure-free.

Based on these remarkable results,

placebo controlled trials are now conducted.

Although not yet formally recognized,

it appears that medical cannabis containing

high CBD and low THC is more effective for child epilepsy.

If officially proven effective,

this is great news for young children with epilepsy,

because of the lack of psychoactive properties of CBD.

探索我們的目錄

免費加入並獲得個性化推薦、更新和優惠。

Coursera 致力於普及全世界最好的教育，它與全球一流大學和機構合作提供在線課程。

© 2018 Coursera Inc. 保留所有權利。

通過 App Store 下載

通過 Google Play 獲取